These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28582422)

  • 41. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
    Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
    Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LRRK2 and the Endolysosomal System in Parkinson's Disease.
    Erb ML; Moore DJ
    J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
    Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila.
    Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N
    Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice.
    Pellegrini L; Hauser DN; Li Y; Mamais A; Beilina A; Kumaran R; Wetzel A; Nixon-Abell J; Heaton G; Rudenko I; Alkaslasi M; Ivanina N; Melrose HL; Cookson MR; Harvey K
    Hum Mol Genet; 2018 Sep; 27(18):3257-3271. PubMed ID: 29917075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.
    Gonzalez-Cano L; Menzl I; Tisserand J; Nicklas S; Schwamborn JC
    Mol Neurobiol; 2018 Apr; 55(4):3490-3498. PubMed ID: 28508149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes.
    Lee JH; Han JH; Kim H; Park SM; Joe EH; Jou I
    Acta Neuropathol Commun; 2019 May; 7(1):68. PubMed ID: 31046837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
    Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum.
    Kritzinger A; Ferger B; Gillardon F; Stierstorfer B; Birk G; Kochanek S; Ciossek T
    Neurobiol Aging; 2018 Jun; 66():97-111. PubMed ID: 29550548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.
    Melachroinou K; Leandrou E; Valkimadi PE; Memou A; Hadjigeorgiou G; Stefanis L; Rideout HJ
    PLoS One; 2016; 11(11):e0166053. PubMed ID: 27832104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains.
    Kim JW; Yin X; Martin I; Xiong Y; Eacker SM; Ingolia NT; Dawson TM; Dawson VL
    eNeuro; 2021; 8(6):. PubMed ID: 34759048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
    Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
    Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years.
    Filippini A; Gennarelli M; Russo I
    Biochem Soc Trans; 2021 Jun; 49(3):1375-1384. PubMed ID: 33960369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.
    Giesert F; Glasl L; Zimprich A; Ernst L; Piccoli G; Stautner C; Zerle J; Hölter SM; Vogt Weisenhorn DM; Wurst W
    Neurobiol Dis; 2017 Sep; 105():179-193. PubMed ID: 28576705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.